Can pyridostigmine (Mestinon) be started in a patient with myasthenia gravis who is in a myasthenic crisis?

Pyridostigmine in Myasthenic Crisis: Approach and Considerations

Yes, pyridostigmine (Mestinon) can be started in a patient with myasthenia gravis in crisis, but the approach depends on crisis severity and should be used cautiously alongside definitive immunotherapy.

Management Algorithm by Crisis Severity

Grade 3-4 (Myasthenic Crisis with Respiratory Compromise)

For severe crisis requiring ICU admission and mechanical ventilation, pyridostigmine is NOT the primary treatment but can be used as adjunctive therapy:

• Primary treatment must be IVIG (2 g/kg IV over 5 days) or plasmapheresis plus corticosteroids 1
• Pyridostigmine may be started at 30 mg PO three times daily and gradually increased to maximum 120 mg PO four times daily as tolerated, based on symptoms 1
• Important caveat: In intubated patients, pyridostigmine may be discontinued or withheld 2
• Continuous IV infusion of pyridostigmine or neostigmine can substitute for IVIG/plasmapheresis only if these are unavailable (particularly relevant in resource-limited settings) 3

Grade 2 (Moderate Symptoms Without Respiratory Failure)

For moderate disease (MGFA class I-II) without respiratory compromise:

• Pyridostigmine starting at 30 mg PO three times daily, gradually increasing to maximum 120 mg PO four times daily as tolerated 1, 4, 1
• Add corticosteroids (prednisone 0.5-1.5 mg/kg orally daily) concurrently 1, 4, 1
• Strongly consider inpatient admission even for Grade 2, as patients can deteriorate rapidly 1

Critical Safety Considerations

Cardiac Monitoring is Mandatory

Patients in myasthenic crisis require careful cardiac monitoring due to significant arrhythmia risk:

• In one retrospective study of 63 myasthenic crises, 17% developed severe cardiac arrhythmia, which was fatal in 6 patients 5
• Obtain baseline troponin, ECG, and consider echocardiogram to evaluate for concomitant myocarditis 1, 4, 1
• Temporary pacing should be provided where clinically indicated 5

Medication Interactions to Avoid

Immediately discontinue medications that worsen myasthenia:

• β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics 4, 1, 4, 1

Dosing Adjustments Required

Patients with myasthenia gravis have increased sensitivity to non-depolarizing neuromuscular blocking agents:

• If intubation is required, use reduced doses (50-75% reduction) of neuromuscular blocking agents with train-of-four monitoring 6, 7
• Pyridostigmine inhibits metabolism of mivacurium and delays recovery 7

Evidence Quality and Practical Considerations

Guideline Consensus

The most recent ASCO 2021 guidelines 1 and ESMO 2022 guidelines 2 consistently recommend pyridostigmine as part of the treatment regimen for myasthenic crisis, though never as monotherapy in severe cases.

Alternative When Standard Therapy Unavailable

A 2021 systematic review found that continuous IV pyridostigmine or neostigmine can serve as a substitute for IVIG/plasmapheresis when these are unavailable, though caution is warranted due to potential cardiac complications 3. A 1997 retrospective study of 63 crises found no significant difference in outcomes between pyridostigmine alone, pyridostigmine plus prednisolone, and plasmapheresis, though all groups had similar cardiac arrhythmia risks 5.

Side Effect Profile

In stable MG patients, 91% report side effects from pyridostigmine (most commonly flatulence, urinary urgency, muscle cramps, blurred vision, hyperhidrosis), with 26% discontinuing due to side effects 8. In crisis situations, the risk-benefit calculation differs, but monitoring remains essential.

Monitoring Requirements

Essential monitoring during crisis management:

• Frequent pulmonary function assessment (negative inspiratory force and vital capacity) 1, 4, 1
• Daily neurologic evaluation 1, 4, 1
• Continuous cardiac monitoring 5
• Serial CPK, troponin to evaluate for concurrent myositis/myocarditis 1, 4, 1

Common Pitfall to Avoid

The most critical error is using pyridostigmine as monotherapy in severe myasthenic crisis. While pyridostigmine provides symptomatic relief by increasing acetylcholine availability at the neuromuscular junction 9, it does not address the underlying autoimmune pathophysiology driving the crisis. Definitive immunotherapy (IVIG or plasmapheresis) must be initiated concurrently in Grade 3-4 disease 1.